Literature DB >> 19203292

Covalent modifiers: an orthogonal approach to drug design.

Michele H Potashman1, Mark E Duggan.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19203292     DOI： 10.1021/jm8008597

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  80 in total

1.  An allenic Pauson-Khand approach to 6,12-guaianolides.

Authors:  Francois Grillet; Chaofeng Huang; Kay M Brummond
Journal:  Org Lett       Date:  2011-11-09       Impact factor: 6.005

Review 2.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  A computational workflow for the design of irreversible inhibitors of protein kinases.

Authors:  Alberto Del Rio; Miriam Sgobba; Marco Daniele Parenti; Gianluca Degliesposti; Rosetta Forestiero; Claudia Percivalle; Pier Franco Conte; Mauro Freccero; Giulio Rastelli
Journal:  J Comput Aided Mol Des       Date:  2010-03-21       Impact factor: 3.686

4.  Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.

Authors:  Giulia Palermo; Davide Branduardi; Matteo Masetti; Alessio Lodola; Marco Mor; Daniele Piomelli; Andrea Cavalli; Marco De Vivo
Journal:  J Med Chem       Date:  2011-09-08       Impact factor: 7.446

Review 5.  Fine-tuning multiprotein complexes using small molecules.

Authors:  Andrea D Thompson; Amanda Dugan; Jason E Gestwicki; Anna K Mapp
Journal:  ACS Chem Biol       Date:  2012-07-23       Impact factor: 5.100

6.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

7.  Synthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer Cells.

Authors:  Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko
Journal:  ChemMedChem       Date:  2015-10-05       Impact factor: 3.466

8.  Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines.

Authors:  Mami Sato; Hirokazu Fuchida; Naoya Shindo; Keiko Kuwata; Keisuke Tokunaga; Guo Xiao-Lin; Ryo Inamori; Keitaro Hosokawa; Kosuke Watari; Tomohiro Shibata; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo; Mayumi Ono; Akio Ojida
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

9.  The Proteome-Wide Potential for Reversible Covalency at Cysteine.

Authors:  Kristine Senkane; Ekaterina V Vinogradova; Radu M Suciu; Vincent M Crowley; Balyn W Zaro; J Michael Bradshaw; Ken A Brameld; Benjamin F Cravatt
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-05       Impact factor: 15.336

10.  An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19.

Authors:  Vincent S Shaw; Mohammadjavad Mohammadi; Josiah A Quinn; Harish Vashisth; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2019-09-22       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.